Zoledronic acid cut fractures 35% and all-cause death 28% in hip-fracture patients
Article suggesting bisphosphonates may extend life, noting a NEJM trial of yearly zoledronic acid after hip fracture that reduced new fractures by 35% and deaths from any cause by 28%. It also mentions possible cancer, heart and aging benefits, which remain speculative.
